The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V76159 | (1R)-Deruxtecan | 2270986-87-1 | (1R)-Deruxtecan is a drug linker conjugate of ADC. |
|
V53011 | (Aminooxy)acetamide-Val-Cit-PAB-MMAE | 2446645-88-9 | (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthesis/preparation of drug-linker conjugates for the preparation of ADCs. |
|
V77364 | (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) | (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1. | |
|
V122163 | (S)-DOTAGA.(SA.FAPi)2 | 2417089-06-4 | (S)-DOTAGA.(SA.FAPi)2 is a radiopharmaceutical precursor that can bind to a radionuclide to form a radiopharmaceutical conjugate (RDC). |
|
V122181 | (S)-JQ-35-C6-O-Ph-C-COOH | (S)-JQ-35-C6-O-Ph-C-COOH is a target protein ligand-linker conjugate that can be used to synthesize PROTACs, such as RAFKBP12. | |
|
V122196 | (S)-N-(4-((3-Methoxy-4-(2-methyl-2H-1,2,3-triazol-4-yl)pyridin-2-yl)amino)-5-propionylpyridin-2-yl)spiro[2.2]pentane-1-carboxamide-d3 | 3062086-74-9 | |
|
V122852 | 1,3-Propanediol-SNS-032 | 1,3-Propanediol-SNS-032 is a target protein ligand and linker conjugate that can be used to synthesize PROTAC CDK9 autophagy degrader 1. | |
|
V54777 | 2',3'-cGAMP-C2-PPA | 2586047-11-0 | 2',3'-cGAMP-C2-PPA is a cyclic dinucleotide stimulating protein of interferon genes (STING) agonist. |
|
V123992 | 2,3,5,6-Tetrafluorophenyl propionate-PEG3-amino-tetraxetan | 2247041-83-2 | 2,3,5,6-Tetrafluorophenyl propionate-PEG3-amino-tetraxetan is a chelating agent and linker conjugate that can be used in the synthesis of radiopharmaceuticals. |
|
V124803 | 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan | 2813269-48-4 | 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a drug-linker conjugate used in antibody-drug conjugates (ADCs). |
|
V111070 | 2-MSP-5-HA-VA-PAB-Exatecan | 2878440-72-1 | 2-MSP-5-HA-Val-Cit-PAB-Exatecan (A-24) is a drug-linker conjugate for antibody-drug conjugates (ADCs). |
|
V114221 | 2-MSP-5-HA-VC-PAB-MMAE | 2878440-80-1 | 2-MSP-5-HA-VC-PAB-MMAE (compound B-1) is an antibody-drug conjugate (ADC)-drug linker conjugate. |
|
V124836 | 2-octynoic acid-BSA | 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). | |
|
V126194 | 4-Arm-PEG10000-Acrylamide | 1818880-26-0 | |
|
V126197 | 4-Arm-PEG10000-Dopamine | 1067250-10-5 | |
|
V126201 | 4-Arm-PEG10000-Hydrazide | 2368232-56-6 | |
|
V126202 | 4-Arm-PEG10000-Isocyanate | 724786-32-7 | |
|
V126204 | 4-Arm-PEG10000-Nitrophenyl carbonate | ||
|
V126205 | 4-Arm-PEG10000-Norbornene | ||
|
V126207 | 4-Arm-PEG10000-OPSS | 3114600-58-4 |